Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

PURPOSE: To conduct a first-in-human phase I study to determine the dose-limiting toxicities (DLT), characterize the pharmacokinetic profile, and document the antitumor activity of IPI-926, a new chemical entity that inhibits the Hedgehog pathway (HhP). EXPERIMENTAL DESIGN: Patients with solid tumor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Jimeno, Antonio, Weiss, Glen J., Miller, Wilson H., Gettinger, Scott, Eigl, Bernard J.C., Chang, Anne Lynne S., Dunbar, Joi, Devens, Shannon, Faia, Kerrie, Skliris, Georgios, Kutok, Jeff, Lewis, Karl D., Tibes, Raoul, Sharfman, William H., Ross, Robert W., Rudin, Charles M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3694426/
https://ncbi.nlm.nih.gov/pubmed/23575478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3654
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi